The investment team seeks to invest in companies with franchise characteristics that are benefiting from an accelerating profit cycle and are trading at a discount to private market value.
As of 31 October 2024 | QTD | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Inception |
---|---|---|---|---|---|---|---|
Advisor Class: APDSX | -1.83 | 11.97 | 35.82 | -8.07 | 6.63 | 9.74 | 9.10 |
Russell 2000® Growth Index | -1.33 | 11.72 | 36.49 | -2.30 | 7.92 | 8.15 | 7.71 |
Russell 2000® Index | -1.44 | 9.56 | 34.07 | -0.05 | 8.50 | 7.94 | 8.93 |
As of 30 September 2024 | QTD | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Inception |
---|---|---|---|---|---|---|---|
Advisor Class: APDSX | 9.04 | 14.06 | 24.61 | -6.36 | 7.40 | 10.65 | 9.19 |
Russell 2000® Growth Index | 8.41 | 13.22 | 27.66 | -0.35 | 8.82 | 8.95 | 7.78 |
Russell 2000® Index | 9.27 | 11.17 | 26.76 | 1.84 | 9.39 | 8.78 | 9.01 |
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Advisor Class: APDSX | 40.33 | 61.19 | -8.77 | -29.36 | 9.51 |
Russell 2000® Growth Index | 28.48 | 34.63 | 2.83 | -26.36 | 18.66 |
Russell 2000® Index | 25.52 | 19.96 | 14.82 | -20.44 | 16.93 |
Semi-Annual Report 31 March 2024 | 1.09% |
---|---|
Prospectus 30 September 2023 | 1.07% |
See prospectus for further details. Semi-Annual Report Figure(s): Unaudited, annualized for the six-month period.
Top 10 Holdings (% of total portfolio as of 31 October 2024) |
|
---|---|
Guidewire Software Inc (Information Technology) | 5.5 |
Halozyme Therapeutics Inc (Health Care) | 4.8 |
Lattice Semiconductor Corp (Information Technology) | 3.8 |
Ascendis Pharma A/S (Health Care) | 3.8 |
Argenx SE (Health Care) | 3.3 |
SPX Technologies Inc (Industrials) | 3.2 |
MACOM Technology Solutions Holdings Inc (Information Technology) | 3.0 |
Veracyte Inc (Health Care) | 3.0 |
Novanta Inc (Information Technology) | 2.7 |
SharkNinja Inc (Consumer Discretionary) | 2.7 |
Total | 35.9% |
Portfolio Statistics (as of 31 October 2024) |
|
---|---|
Median Market Cap (Billions) | $7.0 |
Weighted Avg. Market Cap (Billions) | $8.6 |
Weighted Harmonic Avg. P/E (FY1) | 34.4X |
Weighted Harmonic Avg. P/E (FY2) | 28.9X |
Weighted Avg. Hist. 3 Yr Sales Growth | 30.3% |
Weighted Avg. LT Debt/Capital | 30.2% |
Active Share | 93.0% |
Annual Turnover | 30.1% |
Number of Securities | 58 |
Cash (% of total portfolio) | 1.7% |
Market Cap Distribution (% of portfolio securities as of 31 October 2024) $ in billions |
|
---|---|
5.9+ | 73.2 |
4.1–5.9 | 9.6 |
2.9–4.1 | 6.1 |
1.8–2.9 | 8.7 |
0.0–1.8 | 2.4 |
TOTAL | 100.0% |
Sector Diversification
(% of portfolio securities as of 31 October 2024)